Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 1:00–2:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic
breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Agilent CDx gets expanded approvals

December 2019—The FDA approved Agilent Technologies’ PD-L1 IHC 22C3 pharmDx assay as an aid in identifying patients with esophageal squamous cell carcinoma for treatment with Keytruda (pembrolizumab), an anti-PD-1 therapy manufactured by Merck. Keytruda is approved for patients with recurrent locally advanced or metastatic ESCC whose tumors express PD-L1 (combined positive score ³10), as determined by an FDA-approved test, with disease progression on or after one prior line of systemic therapy.

EC approves Tecentriq-based combo therapy for NSCLC

December 2019—Roche announced that the European Commission has approved and granted marketing authorization for Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel]) for the initial treatment of adults with metastatic non-squamous non-small cell lung cancer who do not have EGFR mutant or ALK-positive NSCLC.

Sysmex, LabCorp extend agreement

December 2019—Sysmex America and LabCorp announced an extension of their hematology automation agreement, to provide LabCorp Diagnostics’ primary reference laboratories with Sysmex America’s latest, upgraded XN-Series technology; the XN-9100 is a scalable, modular automation system that incorporates sample sorting robotics from Yaskawa Motoman.

 

ProciseDx POC platform gets CE mark

November 2019—ProciseDx received the CE mark for its Pro-ciseDx point-of-care diagnostic platform. The company will develop and commercialize near-patient, two- to five-minute tests to precisely quantify diagnostic and treatment
 monitoring markers for inflammatory and autoimmune diseases, such as celiac, and metabolic syndromes, including diabetes and prediabetes.

Qiagen launches NGS panel for rare diseases

November 2019—Qiagen launched its QIAseq Expanded Carrier Screening Panel, which provides identification of targets, genes, and other regions of interest responsible for more than 200 disease indications. The QIAseq panel is integrated with the company’s CLC Genomics Workbench and Clinical Insight (QCI)-Interpret for QIAseq to provide evidence-based, actionable insights.

Randox launches assay for CVD risk assessment

November 2019—Randox introduced a research use only sPLA2-IIA assay for use on a range of clinical chemistry analyzers. The latex-enhanced immunoturbidimetric assay measures sPLA2-IIA mass levels.

MSK-ACCESS gets New York State approval

November 2019—Memorial Sloan Kettering Cancer Center announced that the New York State Department of Health has issued an approval for its Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS) molecular assay. MSK-ACCESS was developed in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and has been clinically validated and implemented by members of MSK’s molecular diagnostics service.

Microlab Prep automated liquid handler

November 2019—Hamilton Company introduced its compact Microlab Prep automated liquid handler, designed to fit on a lab bench or in a biological safety cabinet. The system consists of two independent pipetting channels and a high-speed multiprobe head as well as a configuration containing both pipetting technology types.

AutoGen launches nucleic acid extraction system

November 2019—AutoGen has introduced its fully automated Xtract 16+, for nucleic acid purification from molecular diagnostic, biological, clinical, and forensic sample types. The Xtract 16+ offers nucleic acid isolation from liquid biopsies, plasma, serum, and other body fluids and can process up to 16 samples simultaneously.

MARKETPLACE

TRENDING